Month: August 2022

Release – Avivagen Announces New Dairy Customer in Mexico

Posted on by Admin



Avivagen Announces New Dairy Customer in Mexico

Research, News, and Market Data on Avivagen

  • Family-owned dairy business with established reputation for high-quality products turning to OxC-betaTM to support quality of milk
  • Order procured through Meyenberg International, Avivagen’s Mexican distribution partner

Ottawa, ON /Business Wire/ August 19, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a promising new customer in the Mexican dairy industry.  The agreement will see the customer order 220 kg/month of OxC-betaTM over a three-month period, beginning in September 2022.

“This new agreement represents the continued expansion of OxC-beta™ use within the dairy industry, a key growth market for Avivagen due to its size and positive economics,” said Kym Anthony, Chief Executive Officer, Avivagen Inc. “Mexico remains an important geographic region for us. We are excited about the potential for this first dairy order in the country to lead to others in this vital industry.”

The new customer, based in the Jalisco State region of Mexico, is a thirty-year old, family-owned business with a history of supplying high quality dairy products. The order follows a thorough assessment by the customer of numerous trials previously conducted in Mexico with OxC-beta™, resulting in higher quality milk and yields across a range of important metrics.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, Vietnam and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

 

Forward Looking Statements
This
news release includes certain forward-looking statements that are based upon
the current expectations of management. Forward-looking statements involve
risks and uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements contained herein
that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions “aim”,
“anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”,
“if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”,
“potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and
similar expressions.

Statements set out in this news release relating to the future
growth and prospects for Avivagen, the potential for additional orders for
Avivagen’s products, future shipments and the possibility for OxC-beta™
Livestock to replace antibiotics in livestock feeds as growth promoters are
forward-looking statements. These forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results or events to
differ materially from current expectations. For instance, Avivagen’s products
may not gain market acceptance or regulatory approval in new jurisdictions or
for new applications and may not be widely accepted as a replacement for
antibiotics as growth promoters in livestock feeds due to many factors, many of
which are outside of Avivagen’s control.  Orders may be cancelled for many
reasons outside of Avivagen’s control.   Readers are referred to the
risk factors associated with the business of Avivagen set out in Avivagen’s most
recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen
assumes no obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those reflected in the
forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: 
d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164

Website: 
www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

 


Release – Voyager Announces Coinify Sale

Posted on by Admin

 


Voyager Announces Coinify Sale

Research, News, and Market Data on Voyager Digital

 

NEW YORK, Aug. 17, 2022 /CNW/ – Voyager
Digital Ltd. (“Voyager” or the “Company”) (OTC Pink: VYGVQ) (FRA: UCD) today announced that European Holdings ApS, an indirect wholly-owned subsidiary of Voyager, agreed to sell all of its equity interests in Coinify ApS (“Coinify”) to Ascension ApS, an entity owned by certain members of Coinify management, for US$2 million in cash. An additional, conditional earn-out payment is stipulated in the event of a subsequent sale of Coinify by Ascension ApS within three years following the transaction, thus preserving potential upside for Voyager.

Coinify is a cryptocurrency platform operating in Europe, Asia and other regions, offering individual and corporate cryptocurrency trading, crypto payment processing services, and enterprise solutions via Coinify API. Coinify’s platform is separate and distinct from the Voyager platform.

Voyager purchased Coinify in August 2021; on August 16, 2022, Coinify’s sale was approved by the U.S. Bankruptcy Court for the Southern District of New York, which is overseeing Voyager’s ongoing Chapter 11 restructuring process. The sale of Coinify reduces overall headcount by 15% and eliminates Voyager’s ongoing funding requirements for Coinify of up to US$500,000 per month.

Under Multilateral Instrument 61-101 (“MI 61-101”) the transaction is considered a related party transaction, as the purchaser is controlled by Mark Højgaard, Co-founder and Chief Executive Officer, and Hans Henrik Hoffmeyer, Co-founder and Chief Operating Officer, who are senior officers. The Company relied on the exemption from the minority approval and the formal valuation requirement available to it pursuant to sections 5.7(a) and 5.5(a) of MI 61-101.

About Voyager Digital Ltd.

Voyager Digital Ltd.’s (OTC Pink: VYGVQ) (FRA: UCD) US subsidiary, Voyager Digital, LLC, is a cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost-efficiency to the marketplace. Voyager offers a secure way to trade over 100 different crypto assets using its easy-to-use mobile application. To learn more about the company, please visit https://www.investvoyager.com.

Forward Looking Statements

Certain information in this press release, including, but not limited to, statements regarding future growth and performance of the business, momentum in the businesses, future adoption of digital assets, the terms of the term sheet and any definitive loan documentation and the Company’s anticipated results may constitute forward looking information (collectively, forward-looking statements), which can be identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” (or the negatives) or other similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Voyager’s actual results, performance or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward looking statements are subject to the risk that the global economy, industry, or the Company’s businesses and investments do not perform as anticipated, that revenue or expenses estimates may not be met or may be materially less or more than those anticipated, that parties to whom the Company lends assets are able to repay such loans in full and in a timely manner, that trading momentum does not continue or the demand for trading solutions declines, customer acquisition does not increase as planned, product and international expansion do not occur as planned, risks of compliance with laws and regulations that currently apply or become applicable to the business and those other risks contained in the Company’s public filings, including in its Management Discussion and Analysis and its Annual Information Form (AIF). Factors that could cause actual results of the Company and its businesses to differ materially from those described in such forward-looking statements include, but are not limited to, a decline in the digital asset market or general economic conditions; changes in laws or approaches to regulation, the failure or delay in the adoption of digital assets and the blockchain ecosystem by institutions; changes in the volatility of crypto currency, changes in demand for Bitcoin and Ethereum, changes in the status or classification of cryptocurrency assets, cybersecurity breaches, a delay or failure in developing infrastructure for the trading businesses or achieving mandates and gaining traction; failure to grow assets under management, an adverse development with respect to an issuer or party to the transaction or failure to obtain a required regulatory approval. Readers are cautioned that Assets on Platform and trading volumes fluctuate and may increase and decrease from time to time and that such fluctuations are beyond the Company’s control. Forward-looking statements, past and present performance and trends are not guarantees of future performance, accordingly, you should not put undue reliance on forward-looking statements, current or past performance, or current or past trends. Information identifying assumptions, risks, and uncertainties relating to the Company are contained in its filings with the Canadian securities regulators available at www.sedar.com. The forward-looking statements in this press release are applicable only as of the date of this release or as of the date specified in the relevant forward-looking statement and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after that date or to reflect the occurrence of unanticipated events, except as required by law. The Company assumes no obligation to provide operational updates, except as required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law. Readers are cautioned that past performance is not indicative of future performance and current trends in the business and demand for digital assets may not continue and readers should not put undue reliance on past performance and current trends.

Contacts

Voyager Digital,
Ltd.
Voyager Investor Relations Team 
investor.relations@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

SOURCE Voyager Digital Ltd.


Item 9 Labs (INLB) – Challenging Market Conditions, Reducing to Market Perform

Posted on by Admin

Thursday, August 18, 2022

Item 9 Labs (INLB)
Challenging Market Conditions, Reducing to Market Perform

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by up to 640,000-plus square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit https://investors.item9labscorp.com/.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

3Q Results. Item 9 Labs reported disappointing 3Q results. Revenue was $4.9 million, down 26.3% y-o-y and down 26% sequentially. We had projected $7 million. Gross profit margin declined to 32.2% from 43.2% a year ago. Net loss for the quarter was $5.5 million, or $0.06 per share, versus a net loss of $833,905, or $0.01 per share, in 3Q21. Adjusted EBITDA decreased by $1.9 million to a loss of $1.8 million from a positive $217,995 last year.

Inching Forward. Item 9 is making progress on both the Arizona and Nevada expansions, but at a much slower pace than we had expected. The same with the acquisition of Sessions in Canada and the Herbal Cure location in Colorado. We believe these investments will occur, but timing is uncertain….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Comstock Cellulosic Ethanol Technology Ready For Commercial Deployment

Posted on by Admin



Comstock Cellulosic Ethanol Technology Ready For Commercial Deployment

Research, News, and Market Data on Comstock Mining

Targets First Generation Corn Ethanol Facilities For
Commercialization

VIRGINIA
CITY, NEVADA, AUGUST 18, 2022 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that it is marketing its cellulosic ethanol production technology for construction of commercial scale facilities, with a focus on upgrading pre-existing first generation corn ethanol facilities to convert forestry residuals and other forms of lignocellulosic biomass into cellulosic ethanol at dramatically improved yield, efficiency, and cost when compared to corn.

Comstock’s technology efficiently fractionates wood into purified biointermediates that are uniquely isolated and free of the inhibitors and contaminants that have frustrated prior attempts at broadly commercializing cellulosic fuels technologies. Comstock’s first biointermediate is a purified form of cellulosic sugar that can be used as a chemically identical “drop-in” feedstock in corn ethanol facilities to produce about 80 gallons of advanced cellulosic ethanol per dry ton of woody biomass.

“Using cellulosic sugar as a feedstock will have extraordinary impacts for corn ethanol producers,” said Corrado De Gasperis, Comstock’s executive chairman and chief executive officer. “Woody biomass is a dramatically less expensive and available feedstock and delivers substantial higher revenue from significantly higher lifecycle carbon gains, when compared to corn.” 

The U.S. Environmental Protection Agency (“EPA”) requires and incentivizes compliance with its renewable fuel standards (“RFS”) by assigning renewable identification numbers (“RINs”) to each gallon of renewable fuel produced or imported into the U.S. Different fuel types are assigned different classes of RINs with different market values based on the degree to which each fuel type reduces greenhouse gas (“GHG”) emissions over fossil petroleum sources. California and various other states have now also enacted low carbon fuels standards which provide significant additional incentives. In short, the greater the GHG reduction, the lower the carbon intensity (“CI”) score, the higher the selling price of the resulting fuel.

Under current market conditions, our cellulosic ethanol would have a market value in California of approximately $6.30 per gallon, as compared to just over $3.00 per gallon for corn ethanol. Under current market conditions and prices, a typical 100 million gallon corn ethanol producer that upgrades its facility to produce an additional 20 million gallons of cellulosic ethanol would increase revenue by more than 30%, or over $125 million per year.

“Our goal is to accelerate the commercialization of decarbonizing technologies,” concluded De Gasperis. “We are ready to enable dramatic improvements in GHG reductions and ethanol profitability today, with existing corn-based producers.”

Comstock is evaluating a number of existing first generation corn ethanol facilities for upgrades to and construction of co-located commercial scale cellulosic ethanol production. Additional information is available from Comstock’s business development group. Please see contact information below.  

About
Comstock

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complementary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Forward-Looking
Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future prices and sales of, and demand for, our products; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management considering their experience and their perception of historical and current trends, current conditions, possible future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, mercury remediation and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mercury remediation, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with mercury remediation, metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, mercury remediation technology and efficacy, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Comstock Cellulosic Fuels business development contact information:

 

 

David Winsness
President, Cellulosic Fuels
winsness@comstockmining.com

Chad Michael Black
Director-Business Development cmblack@comstockmining.com


How Long Will the Current Wave of Meme Stock Investing Last?

Posted on by Admin 



Source: Bloomberg TV (August 17, 2022)


Meme Stock Frenzy 2.0 – WallStreetBets Founder Thinks it Will Continue

Is Bed Bath and Beyond (BBBY) going to rebound? Are AMC Theatres (AMC) and GameStop (GME) just beginning to make another attempt at reaching the moon. In a Bloomberg interview on Tuesday (August 17), WallStreetBets’ founder Jaime Rogozinski shared his thoughts. The interview is made more interesting in that it was conducted before news that Ryan Cohen, GameStop chairman and Chewy (CHWY) founder, filed to sell his entire stake in meme stock BBBY. This move gives pause to meme investors because the value of Cohen’s holdings in Bed Bath and Beyond was roughly 10% of BBBY market value. Rogozinski said he believes meme stock investors are “probably aiming to the moon.”

Meme Momentum

Rogozinski was asked if he was at all surprised to see so much trading come back in light of the lull in self-directed investor activity and inflation-related financial concerns. “I’m not really; summer vacation is over,” he then continued, “that’s when the activity gets to kick back up.” Jaime recognizes the momentum we had seen previously from WallStreetBets had “whimpered down” but he said goes in cycles just like the regular economy. He also pointed out that it would be impossible to retain momentum and make the kind of moves stocks like Bed Bath and Beyond and other meme stocks make without shifts in cyclical momentum.


Image: A Section of Ryan Cohen’s (RC Ventures) SEC form 144

Different Drivers?

Responding to a question about whether the drivers are different this time, Mr. Rogozinski said, “The drivers appear to be the same.” He pointed out that it is early in the cycle, but “we have the meme component that, everyone’s talking about it, the chatter and enthusiasm, you have a stock from a company that is relatively distressed, you have a high short float,” then he said something that may cause an investor in at least one of the current meme stocks to pay more attention, Rogozinski continued, “you have Ryan Cohen dipping his hands into this particular stock and giving his Midas touch to it,” as he expressed that the moves again have a lot of the same components.

WallStreetBets Leader

He was asked specifically about Ryan Cohen, which is interesting to review the morning after the activist investor filed to sell his shares of BBBY and a move to own calls that would expose him to gains for far fewer shares. Rogozinski, without knowledge of Cohen’s plans, said, “There is no one individual. I think that if a high-profile individual decides to get into a stock or just to add to the thesis or find some confirmation bias, then it’s always helpful.” The WallStreetBets founder added, “It could be him, or it can be Elon Musk,” or any one of a number of “quirky public figures or CEOs” that have stock market influence, so it’s hard to pinpoint.

“The thing about retail trading or WallStreetBets is that it’s a collective, right – there is no captain of the ship saying ‘this is where we’re sailing’ the power comes from the numbers, the power comes from the fact that there are collective decisions that are made.” He reemphasized, “There is no individual that makes that choice.”

Will Meme Stock Frenzy Continue?

Jaime Rogazinski thinks the current meme stock resurgence has room to continue. He said, “As long as we don’t disable the BUY button, we probably have a decent chance to keep going forward.” He said he is not active in this move himself; the reason given is that to be profitable, he thinks he would need to have a strategy, and he personally doesn’t have a strategy yet for these markets.

Asked if meme stock frenzy sustainability expectations should change with an entirely different economic backdrop, Rogozinski said he believes there is a bit more of an eye toward the big picture this time. But the fundamentals and price discovery that meme stock investors are adhering to are supply and demand. Standard fundamentals, in his analysis, don’t seem to support GameStop’s price sustainability he used as an example.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Will Bankrupt Revlon Get a Makeover from a Self-Directed Investor Frenzy?

AMC Announces Peculiar Dividend and a New Class of Company Stock




Founder of WallStreetBets has a New Idea for CopyCat Investors

An Archive of Memes from Stonks’ Heyday in 2021

Sources

https://sec.report/Form/144-PAPER/43719

https://www.youtube.com/watch?v=Uv7j1hAhGSk


Stay up to date. Follow us:

 

Release – Orion Group Holdings Names Travis J. Boone as President and Chief Executive Officer

Posted on by Admin

 


Orion Group Holdings Names Travis J. Boone as President and Chief Executive Officer

Research, News, and Market Data on Orion Group Holdings

Aug 18, 2022

HOUSTON, Aug. 18, 2022 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that Travis Boone has been named President and Chief Executive Officer and member of the Board of Directors, effective September 12, 2022. Austin J. Shanfelter will step down as Interim CEO at that time and will continue to serve as Orion’s Executive Chairman during a short transition period. 

Mr. Boone served as a regional Chief Executive of AECOM and legacy companies since May 2017 and other key positions since 1999. From 1986 to 1999 he held various positions with several contracting companies in the utility/pipeline construction and commercial building construction industries. He is a Professional Engineer and Board-Certified Safety Professional. Mr. Boone graduated from New Mexico State University with a Bachelor of Science degree in Civil/Structural Engineering and has an Associate of Arts degree in Business Administration from Mid-American Christian University.

“On behalf of the Board of Directors and Orion Group Team, I would like to welcome Travis as our new President and Chief Executive Officer. Travis brings a wealth of industry knowledge, experience, and leadership to Orion. He has a proven track record of success, which we expect will have a significant impact on improving Orion’s performance and position it well for growth and success,” said Austin Shanfelter.

Mr. Boone stated, “I am honored to join Orion Group Holdings as its next President and Chief Executive Officer at such an important time in the Company’s history. I regard Orion Group as an industry leader and believe there are significant opportunities to grow the company. I look forward to working with and leading a talented team to continue improving performance and maximizing market value.”

About Orion Group
Holdings, Inc.

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas.

Forward-Looking
Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Source: Orion Group Holdings, Inc.


Primary Logo

Source: Orion Group Holdings, Inc.


The GEO Group (GEO) – Debt Restructuring Approved

Posted on by Admin

Thursday, August 18, 2022

The GEO Group (GEO)
Debt Restructuring Approved

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Push Back That Wall. GEO received the required participation of its creditors to close on the debt restructuring. The $2 billion debt wall due over the next four years, now has maturities of $125 million in 2023; approximately $165 million in 2024; approximately $341 million in 2026; approximately $1.1 billion in 2027; and approximately $526 million in 2028, providing substantial flexibility of the Company.

Go Forward. Following the closing of the transactions, GEO will have approximately $200 million in domestic unrestricted cash and cash equivalents and total liquidity of approximately $375 million. Assuming consistent financial performance across its business units, over the next two years, GEO expects to be able to reduce net recourse debt by $200­­–250 million annually. …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Drug Companies Impacted by the U.S. Shifting Covid-19 Care to Patients

Posted on by Admin 



Image Credit: Pexels (Kampus Productions)


Covid-19 Vaccine and Healthcare Responsibility to Begin Falling on the Patient

The Department of Health and Human Services (HHS) is scheduled to hold a planning session on Aug. 30 that will include representatives of stakeholders involved with Covid-19 prevention and treatment. This includes pharmaceutical companies, state health departments, health insurers, and pharmacies. Under the direction of the Biden administration, the HHS plans to end the practice of taxpayer-funded Covid-19 vaccines and Covid-19 therapies.


Objectives

The goal of the planning session is to shift more control of pricing and coverage to the healthcare industry. This could increase costs for consumers and generate sales for companies.

Since the start of the pandemic-related programs, the expectation has been that the costs associated with Covid-19 shots and therapies would shift to individuals choosing them and away from the federal government. With funding for the pandemic response disappearing, along with the global outbreak itself, officials are now mapping out the transition of care to fall on the users.


Businesses Affected

The earnings and market implications to certain companies could be significant, depending on the outcome of the planning sessions.  As of February 2022, pharmaceutical companies, including Pfizer (PFE) and Moderna (MRNA) reported at least $79 billion in combined global sales of Covid-19 vaccines and therapies for 2021. Pfizer also reported $8.1 billion in global sales during the second quarter for its Covid-19 treatment, Paxlovid.

As of mid-February, no money was left in HHS’s public-health and social-services emergency fund for healthcare providers. This month (August), the administration stopped supplying monoclonal antibody treatments. Eli Lilly & Co. (LLY) now focuses on sales of its Covid-19 monoclonal antibody treatment to states, hospitals, and other healthcare providers. As far as vaccines, the Biden administration has already signed purchase agreements for updated doses for the fall.

The impact of shifting vaccine procurement to businesses means that each insurer and pharmacy benefit manager may be negotiating with drug manufacturers. The impact on prices is they would likely be higher than what the federal government has paid, and health insurance premiums could come under upward pressure as well.


Timeframe

Shifting payments for Covid-19 drugs and vaccines to the commercial market is expected to take months. During the upcoming August meeting, officials and company representatives are expected to discuss regulatory issues and access to vaccines and treatment, along with reimbursement and coverage, for the uninsured.

The change presents challenges, including what, if anything, to do with roughly 30 million people without health insurance. Currently, the federal government has been purchasing Covid-19 vaccines and treatments and making them available at no user cost during the pandemic. Medicaid and Medicare don’t cover antivirals; they were approved under an emergency-use authorization. This will all have to be addressed.


Take Away

The use of government funding during the pandemic was a boon to many companies. These companies may now be asked to embrace something closer to the “old normal” which could be a more difficult road. The timeline toward transitioning is long and there are many considerations for each stakeholder affected.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Monkeypox Treatments and Vaccines are Creating Investor Opportunities

Where are Consumers Most Likely to Spend Their Leisure Budget?




Biotech Stocks Outperformance Factors – Will they Continue?

Michael Burry Says the Cure is Worse than the Disease


Stay up to date. Follow us:

 

Release – Vera Bradley Makes Move Into Metaverse With Utility-Driven NFTs To Celebrate 40th Anniversary

Posted on by Admin



Vera Bradley Makes Move Into Metaverse With Utility-Driven NFTs To Celebrate 40th Anniversary

Research, News, and Market Data on Vera Bradley

Genesis NFT Drop Comes With Limited-Edition Jilly Bag, Plus 100% Of Vera Bradley’s Primary Net Proceeds From 2nd NFT Drop To Benefit The Vera Bradley Foundation For Breast Cancer

FORT WAYNE, Ind., Aug. 17, 2022 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA), the parent company of iconic lifestyle brand and leading American bag and luggage brand Vera Bradley, announced the World of Vera Bradley via Discord and Twitter. This new digital concept will take customers on a journey into the metaverse, bringing together the brand’s past, present, and future through its upcoming NFT (non-fungible token) collections.

Pioneering colorful and beautiful travel solutions for women since 1982, Vera Bradley now aims to create an experience that bridges the physical and digital worlds and provides a space for women to explore and learn about Web3 through the World of Vera Bradley. Easy to access through worldofverabradley.com, the World of Vera Bradley will also be the point-of-purchase for Vera Bradley’s NFT collections, the first of which is slated to launch in September during New York Fashion Week.

Aptly named the Heritage Pass, Vera Bradley’s genesis NFT will celebrate the brand’s 40th anniversary and feature one animated image of Vera Bradley’s coveted throwback Jilly Bag in four archived prints. Available for purchase on September 14, 2022, and priced to sell at $82.00 USD*, each of the 440 Heritage Pass NFT tokens will function as a Mint Pass and come with a physical, limited-edition Jilly Bag in one of the four heritage prints featured in the NFT. Anticipation of the unknown will add to the excitement of the Heritage Pass, as buyers will receive a Jilly Bag in one of four surprise patterns. Additionally, first-adopters will be rewarded with early access to purchase the second Vera Bradley NFT, launching in October.

Available for presale on October 1 and 2 and for public sale on October 3, 2022, Vera Bradley’s second NFT drop, the 1982 Collection, will be comprised of 1,982 generative backgrounds derived from 40 archived prints to commemorate the year the company was founded. Priced at $19.82 USD*, the 1982 Collection will attract both crypto lovers and breast cancer awareness supporters alike with 100% of Vera Bradley’s primary net proceeds benefiting the Vera Bradley Foundation for Breast Cancer, focusing its unique utility on advocacy and fundraising.

“The World of Vera Bradley brings Vera Bradley’s brand vision for an interconnected future and Web3 world to life,” states Daren Hull, Brand President, Vera Bradley, “Beyond technology, Web3 will continue to evolve and shape ownership in the next generation. We believe NFT projects like ours, rooted in strong fundamentals and a commitment to maximizing the fundraising impact to the Vera Bradley Foundation for Breast Cancer, will be the future of Web3.”

Jennifer Bova, VP of Marketing, Vera Bradley continues, “With the launch of the World of Vera Bradley and our first NFT collections, we will create an authentic and connected community of digital asset holders through innovation, vision, and a consumer-first approach. This is another experience to strengthen Vera Bradley’s sisterhood, utilizing Web3 and fundraising for the Vera Bradley Foundation for Breast Cancer.”

Both Vera Bradley NFT Collections will be available for purchase through the World of Vera Bradley’s digital destination (www.worldofverabradley.com) using a credit card, or via Open Sea using ETH.

ABOUT VERA BRADLEY:
Vera Bradley, based in Fort Wayne, Indiana, is a leading designer of women’s handbags, luggage and other travel items, fashion and home accessories, and unique gifts. Founded in 1982 by friends Barbara Bradley Baekgaard and Patricia R. Miller, the brand is known for its innovative designs, iconic patterns, and brilliant colors that inspire and connect women unlike any other brand in the global marketplace. Visit www.verabradley.com and follow @verabradley to learn more.

ABOUT VERA BRADLEY FOUNDATION FOR BREAST CANCER:
The 
Vera Bradley Foundation
for Breast Cancer raises funds for breast cancer research to find a cure and to improve the lives of the many affected by this disease. The Foundation has contributed $37.5 million to the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine. The Center is focused on developing and dramatically improving therapies for some of the most difficult-to-treat types of breast cancer. Funds are raised through special events, partner events, and individual donations.

CONTACTS:
Email: mediacontact@verabradley.com
Phone: 877-708-VERA (8372)
Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d47a7824-51ff-42a7-9006-b437d3802e4b and https://www.globenewswire.com/NewsRoom/AttachmentNg/90dccc59-03b9-467a-9f01-8b1889c967a5.
*Please Note: The exact USD retail price will depend on gas prices at time of purchase.

 


Will Gold’s Direction Continue to Point South?

Posted on by Admin 

Image Credit: Valentin Antonucci (Pexels)


Ignoring Bearish Fundamentals May Push Gold to New 2022 Lows

With commodities getting whacked on Aug. 15, gold, silver, and mining stocks materially underperformed the S&P 500. Moreover, with bond and commodities markets more attentive to Fed officials’ hawkish threats, the general stock market is the lone member pricing in a dovish pivot.

However, since hope often leads to disappointment when it’s built on a sloppy foundation, the bulls don’t realize that the Fed’s inflation fight will be one of the most challenging fundamental contests in decades. Therefore, while investors believe that the hard work is done once the Consumer Price Index (CPI) slows, the reality is that the difficult times have only just begun.

For example, the New York Fed released its Empire State Manufacturing Survey on Aug. 15. An excerpt read:

“Business activity declined sharply in New York State, according to firms responding to the August 2022 Empire State Manufacturing Survey. The headline general business conditions index plummeted forty-two points to -31.3. New orders and shipments plunged, and unfilled orders declined. Delivery times held steady for the first time in nearly two years, and inventories edged higher.”

Source: New York Fed

However, while output fell off a cliff, there was “a small increase in employment,” and the prices received index moved higher.


Source: New York Fed

Thus, while the sharp decline in output should have culminated in lower prices, the data highlights just how sticky inflation has become. Furthermore, if prices don’t decline when output craters in New York State, how can investors expect them to fall when S&P 500 companies still have resilient demand?

Furthermore, the report revealed:

“The delivery times index declined to around zero, indicating that delivery times held steady, the first month they have not lengthened in nearly two years.”


Source: New York Fed

To explain, the Fed and the consensus blamed supply-chain disruptions for the recent bout of inflation. In a nutshell: COVID-19 restrictions suffocated shipping activity, and suppliers didn’t have the inventory to meet demand. Therefore, order backlogs surged, and prices increased as manufacturers bid against one another to obtain the scarce inputs.

However, while the New York Fed’s delivery times index is back near pre-COVID-19 levels, its prices received index is not. As a result, the normalization of supply chains has done little to curb inflation, and investors materially underestimate the challenges that lie ahead.


1970s Here Were Come

While the GDXJ ETF diverged from the S&P 500 on Aug. 15, a sharp decline in the latter would spell immense trouble for the former. Therefore, the general stock market is an important component of our investment thesis. Moreover, while the S&P 500 continued its ascent and the bulls have their sights set on new all-time highs, I warned on Aug. 15 that the fundamental outlook signals the exact opposite. I wrote:

After the FFR peaked in July 1973, the Fed cut interest rates to help support a weakening U.S. economy. However, with inflation still unanchored, the policy mistake led to an even higher FFR during the depths of the recession (the gray area).

Please see below:

Likewise, the S&P 500 initially celebrated the dovish pivot. With uninformed investors assuming that cutting interest rates was the appropriate response, a sharp rally occurred in July 1973, followed by a sharp pullback and then another rally to a higher high. As a result, don’t you think the crowd was calling for a new bull market from July through October 1973? However, unanchored inflation forced the Fed to reverse course and the S&P 500 fell off a cliff.

Thus, we find ourselves in the same situation. With the consensus underestimating the destructive nature of inflation and overestimating the Fed’s ability, the bulls should suffer a crisis of confidence over the medium term.

Please see below:

To explain, the red line above tracks the year-over-year (YoY) percentage change in the headline CPI, while the green line above tracks the monthly change in U.S. nonfarm payrolls. For context, the consensus cites near-record job openings and robust payroll growth as evidence for why only a mild recession can occur (if one occurs at all).

However, the chart above highlights how unanchored inflation torpedoed that narrative in the 1970s. If you analyze the shaded gray areas (recessions), notice how the green line remained positive during the early stages of the recessions in 1970, 1974, and 1980. In a nutshell: monthly payroll growth stayed positive during the outset of all three recessions.

However, if you focus your attention on the sharp drops in the green line near the end of the 1970, 1974, and 1980 recessions (negative monthly payrolls prints), you can see that reality re-emerged and the U.S. labor market suffered mightily. Moreover, negative payroll growth was also present during the 1982 recession, but inflation was declining at that time.

As such, it’s important to remember that U.S. nonfarm payrolls growth has been positive in every month except one since May 2020. Furthermore, the U.S. unemployment rate declined to 3.5% in July – its lowest level in ~50 years – and its relationship with the CPI has similar implications.

Please see below:

To explain, the red line above tracks the YoY percentage change in the headline CPI, while the green line above tracks the U.S. unemployment rate. As you can see, the 1970, 1974, and 1980 recessions culminated with high inflation and delayed spikes in unemployment. Moreover, while the 1982 recession had a diverging relationship, Paul Volcker made it his mission to eradicate inflation at all costs. Therefore, he understood the severity of the problem and didn’t want a repeat of the outcomes from 1970, 1974, and 1980.

Furthermore, notice how the U.S. unemployment rate always bottoms before a recession? Remember, bear markets don’t end with the U.S. unemployment rate at a ~50-year low; they begin with the metric at a ~50-year low.

To that point, even modern history highlights the uninformed nature of the bulls’ thesis.

To explain, the recessions near 1990, 2000, and 2008 all began with cycle-low U.S. unemployment rates (the green line) and rising inflation (the red line). In addition, if you analyze the right side of the chart, you can see that the gap between the two is one for the ages. As such, can you guess where this story is headed next?

Finally, while I warned repeatedly that market participants underestimated the demand side of the inflation equation, the consensus still believes that supply-chain issues are the primary driver. However, with unanchored wage inflation poised to keep the pricing pressures uplifted for much longer than investors realize, the Fed will need to push the U.S. federal funds rate (FFR) much higher than 3%.

To explain, the red line above tracks the YoY percentage change in U.S. nonfarm unit labor costs from the late 1960s until today. For context, the metric combines wages and productivity to determine the labor costs incurred by U.S. businesses. In a nutshell: when the red line rises, labor is more expensive.

If you analyze the peaks, notice how unanchored labor costs were present during the 1970s and 1980s recessions. Furthermore, even modern history shows that spikes in labor costs occurred before/during the recessions near 1990, 2000, and 2008.

More importantly, the current reading is higher than 1970 and is only surpassed by 1974, 1980, and 1982. Thus, it may seem counterintuitive, but low unemployment, high wages, and high job openings (end-of-cycle metrics) are bearish, not bullish. As a result, the bulls are in la-la land, and the ‘this time is different crowd should suffer mightily when reality re-emerges.


The Bottom Line

While the PMs have rallied recently, they’re still underperforming the S&P 500 and the NASDAQ Composite. Moreover, with the latter ignoring the bearish fundamentals at their own peril, a sharp re-rating of the general stock market should help push gold, silver and mining stocks to new 2022 lows. Likewise, while the bulls want you to believe that all is well on Wall Street, their success hinges on outcomes materializing that haven’t occurred in 50+ years.

In conclusion, the PMs declined on Aug. 15, as most of the commodity complex was crushed. However, with little fear present in today’s financial markets, asset prices are far from their fundamental values. As such, the medium-term outlook is profoundly bearish, and it’s likely only a matter of time before sentiment reflects these realities.

About the Author:

Przemyslaw Radomski, CFA  (PR) writes and publishes articles as Editor-in-Chief at Sunshine Profits. His work underscores his
disposition of being passionately curious about market behavior. He uses his
statistical and financial background to question the common views and profit from
the misconceptions.


Suggested Content



Dollar Strength Impacts Commodity Prices, Money Flow, and Worldwide Inflation

Why Natural Gas Opportunities Should Not Always be Lumped in With the Oil Sector





Elon Musk Talks About Tesla Bots, Birth Rates, and Federal Incentives

The More Impactful Fed Moves May Not Make Headline News

Stay up to date. Follow us:

 

Has the Monkeypox Ship Sailed for Investors?

Posted on by Admin 

Image Credit: NIAID (Flickr)


Monkeypox Treatments and Vaccines are Creating Investor Opportunities

Investors are joining healthcare providers and public officials as they all gear up for what is now being called a public health emergency. Monkeypox was a rare disease that has been infecting humans since 1970. The latest global monkeypox outbreak, while significant, has demonstrated the known disease is less of a concern than the novel coronavirus, which made its way to the U.S. in 2020. However, the U.S. President, the WHO, and other global authorities have declared monkeypox an emergency. They have begun stockpiling pills, patches, and vaccines in anticipation of a full-scale effort to prevent the spread.

As authorities declare their intentions, investors are working toward understanding the disease and the likely treatments. From this, they forecast which they expect will be most supported, effectively “the winners.” This list is likely to include everything from antiseptic manufacturers, to contact tracing products, condom manufacturers, and of course, preventatives and treatments. It is the medical side of preventing and treating the diseases that is already getting support from deep-pocket governments.

The virus continues to spread. There were 12,688 confirmed monkeypox cases in the U.S. on Tuesday (August 16), according to the CDC. This is an increase from 9,492 the previous Tuesday. The U.S. has more confirmed cases than any other country. Outside the U.S.,  Brazil, France, Germany, Spain, and the U.K. each also have thousands of monkeypox cases.

Investor’s Attention

Bavarian Nordic (BAVA.CO), a Copenhagen-listed company, is a Danish biotech vaccine manufacturer. The company manufactures the only authorized vaccine against monkeypox in the world. Bavarian Nordic has received an onslaught of requests for supplies of the shot. While they have a monopoly on an approved vaccine, they told Bloomberg today (August 17), “Demand keeps rising, and it’s no longer certain that we can continue to meet the demand we’re facing even with the upgrade of our existing manufacturing site in Denmark.” This could provide investors with additional opportunity if they choose to outsource manufacturing of their Jynneos monkeypox vaccine.

BAVA is up 164% since May 1.

Siga Technologies (SIGA), is a U.S.-based Nasdaq listed company. Siga manufactures a therapy for smallpox that is not yet approved in the U.S. for monkeypox called Tpoxx. Tpoxx has been approved for use for monkeypox in the UK and other affected countries outside the U.S.

SIGA is up 266% since May 1. 

Tonix Pharmaceuticals (TNXP), is a U.S.-based Nasdaq listed company that is developing a live form of the horsepox virus to be used as a preventative for monkeypox and smallpox infections. In January 2020, the company announced the results of test studies in non-human primates that were challenged with monkeypox. In that study, the safety of TNX-801 was exhibited by stable body weights and body temperatures for all treated animals.  

Read the most recent TNXP research
report by Noble Capital Markets.

 

Take Away

Just a short time ago, investors were made aware of how profitable a declared healthcare crisis can be for companies and their investors. Obviously, those medically impacted benefit as well. While the growing monkeypox outbreak does not pose as large a threat as Covid-19, it provides an interesting opportunity as it is already declared a health threat. The emergency status means there will be significant financial support to curtail and eliminate the outbreak. Learning early where that will be could be profitable

Investors can research small and microcap biotech and pharmaceutical companies on Channelchek by signing-up to have access to the complete website.

Paul Hoffman

Managing Editor, Channelchek


Suggested Content



Is Biotech’s Outperformance Reaching a New Stage of Development?

Why They Use Antibiotics on the Covid Virus





Capitalism versus Coronavirus (May 2020)

Tonix Pharmaceuticals (TNXP) NobleCon18 Presentation Replay

Sources

https://www.whitehouse.gov/briefing-room/press-briefings/2022/08/11/press-briefing-by-white-house-monkeypox-response-team-and-public-health-officials/

https://www.hpnonline.com/infection-prevention/article/21277723/mayo-clinic-expertise-on-monkeypox

https://www.cdc.gov/poxvirus/monkeypox/about.html

https://www.npr.org/sections/health-shots/2022/08/04/1115676160/white-house-declares-monkeypox-a-public-health-emergency

https://www.cdc.gov/poxvirus/monkeypox/sexualhealth/index.html

https://www.pinknews.co.uk/2022/07/16/monkeypox-sexually-transmitted-semen-condom-sex/

https://www.barrons.com/articles/monkeypox-vaccine-supply-bavarian-nordic-51660735711

Stay up to date. Follow us:

 

Release – BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022

Posted on by Admin



BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022

News and Market Data on BioSig Technologies

August 17, 2022

Leading Medical Center of Excellence Physician will discuss
integrating the PURE EP™ System into their practice and procedural workflow

Westport, CT, Aug. 17, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced  its participation in the Kansas City Heart Rhythm Symposium, being held on August 20-21, 2022. The Company’s PURE EP ™ System,  a non-invasive device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology, will be highlighted in a physician presentation during the symposium.

The presentation, titled, “Going Back to Old School –
Leveraging EGMs to Improve Efficacy, Safety of Ablation” will be conducted during a symposium session beginning at 12:30 PM ET on Sunday, August 21, 2022. Hicham El Masry. M.D., a Cardiac Electrophysiologist at Mayo Clinic’s Arizona Campus, will discuss the clinical advantages of the PURE EP™ System and the impact the technology has made on his electrophysiology (EP) practice and procedural workflow.  

During the event, the Company’s clinical and commercial teams will host product demonstrations that will showcase the latest advancements and software features of its PURE EP ™ System. The Company will also provide an update on developments in its clinical pipeline. 

“We are looking forward to returning to KCHRS, with the latest advancements of the PURE EP™ System that have been demonstrated and featured by one of our earliest adopters,” commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. “We would like to thank Dr. Lakkireddy for allowing us to be a part of such an important meeting and Dr. El Masry for representing our technology at the symposium.”

To
register for the event, please click here.

BioSig recently announced the commencement of a physician-initiated research protocol that will analyze the signals acquired by its PURE EP™ System during Radiofrequency (RF) ablation. Led by Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, the single center study underway at Overland Park Regional Medical Center, is officially registered with clinicaltrials.gov [NCT05464537], and includes 30 participants with paroxysmal atrial fibrillation (AF) undergoing pulmonary vein isolation (PVI).

About
KCHRS 2022
The Kansas City Heart Rhythm Symposium is an EP-focused medical education event for the neighboring four state regions. A variety of topics will provide specialists and generalists an update on the evolution of disease processes, diagnostic tools, therapeutic strategies and ethical issues in the advancement of patient care. To learn more visit, www.kchrs.com.

About
BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System, is a novel signal processing and acquisition platform designed to extract advanced diagnostic and therapeutic data that enhances physician workflow and increases throughput. PURE EP™ was engineered to address the limitations of existing EP technologies by empowering physicians with superior signals and actionable insights.

The Company is in a national commercial launch of the PURE EP™ System. The technology is in regular use in some of the country’s leading centers of excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

Clinical data acquired by the PURE EP™ System in a multi-center study at centers of excellence including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center  was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(T.M.) signals over conventional sources.

Forward-looking
Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market conditions and the Company’s intended use of proceeds, (ii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

 


Release – MustGrow Biologics and Sumitomo Corporation Announce Extension of Exclusive Agreement and Program Advancement

Posted on by Admin



MustGrow Biologics and Sumitomo Corporation Announce Extension of Exclusive Agreement and Program Advancement

Research, News, and Market Data on MustGrow Biologics

  • Sumitomo Corporation has extended the option for exclusive testing with MustGrow’s technology for preplant soil fumigation, bioherbicide, postharvest and food preservation for potatoes, and bananas in North, Central, and South America.
  • Sumitomo Corporation continues to demonstrate positive levels of efficacy utilizing MustGrow’s technology in comparison to synthetic chemical standards.
  • Sumitomo Corporation to continue driving all field development, including regulatory and market assessment work necessary for commercialization.

TOKYO,
JAPAN & SASKATOON, SK, CANADA – August 17, 2022 – Sumitomo Corporation
(TYO: 8053) (OTC: SSUMY) and MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF)
(FRA: 0C0) (“MustGrow”) have signed an extension to their Exclusive Evaluation and Option Agreement (the “Extension
Agreement”) to continue developing MustGrow’s mustard-based technology across the Americas.

Pursuant to the Extension Agreement, MustGrow has granted Sumitomo Corporation the exclusive right to continue developing MustGrow’s mustard-based technologies for preplant soil fumigation, bioherbicide, and postharvest and food preservation for potatoes and bananas in North, Central, and South America for an additional option period (the “Extension
Period”). Over the span of the initial option period, Sumitomo Corporation’s evaluation efforts demonstrated positive levels of efficacy utilizing MustGrow’s technology in comparison to certain synthetic chemical standards. These positive tests, conducted across the Americas, resulted in the parties’ desire to extend the term of the Exclusive Evaluation and Option Agreement. During the Extension Period, Sumitomo Corporation plans to continue to drive all field development, regulatory and market assessment work necessary for commercialization.

The global crop protection chemicals market size was valued at USD 63.7 billion in 2020, and is projected to reach a value of USD 74.1 billion by 2025.(1) The growth of this market is attributed to the increasing need for food security of the growing global population. A large growth market is biopesticides, which are pesticides produced naturally, with minimum usage of chemicals. Due to rising environmental concerns and awareness of the pollution potential and health hazards of many synthetic conventional pesticides, the demand for biopesticides has been rising steadily in all parts of the world.

SUMITOMO CORPORATION COMMENT

“We are convinced that BioSolutions combined with AgTech are the future of agriculture and fundamental pillars where we are focusing our investment in the development of new solutions. After evaluating and verifying the effectiveness of the MustGrow technology in different crops with different application techniques, we are very glad to take a step forward in the collaboration with MustGrow.”

“We expect to strengthen this collaboration to accelerate the development to make this safe and effective tool available to farmers as soon as possible for a more sustainable agriculture,” said Marcos Mares, Head of Global Business Development in Sumitomo Corporation AgriScience Department.

MUSTGROW COMMENT

“We are very excited to have Sumitomo Corporation commit to the next stage of our agreement. Considering that close to 45% of the global food is produced in North, Central and South America, it is critical to continue to innovate and develop technologies like ours,” said Corey Giasson, MustGrow’s President & CEO. “Having an organization like Sumitomo Corporation demonstrate the benefits in field and commit to move forward with our technologies is a great step to providing a sustainable solution for farmers globally.”

Source 1 – https://www.marketsandmarkets.com/Market-Reports/crop-protection-380.html

About
Sumitomo Corporation

 Sumitomo Corporation (“SC”) is a leading Fortune 500 global trading and business investment company with 131 locations (Japan: 20, Overseas: 111) in 66 countries and regions. The entire SC group consists of more than 900 companies. SC conducts commodity transactions in all industries utilizing worldwide networks, provides customers with financing, serves as an organizer and a coordinator for various projects, and invests in companies to promote greater growth potential. SC’s core business areas include six business units: Metal Products; Transportation & Construction Systems; Infrastructure; Media & Digital; Living Related & Real Estate; and Mineral Resources, Energy, Chemical & Electronics, and one initiative: Energy Innovation.

SC began exporting business of crop protection products in the 1970s, and has expanded its business realm to importing and wholesaling in 37 countries with 40 companies. Leveraging these broad networks and its long experience in the industry, SC has further expanded its activities to make a multifaceted contribution to global agriculture, such as the direct sales of agricultural inputs to farmers and the utilization of cutting-edge agricultural technologies.

For more information, please visit: https://www.sumitomocorp.com/en/jp.

About
MustGrow

MustGrow is an agriculture biotech company developing organic biopesticides and bioherbicides by harnessing the natural defense mechanism of the mustard plant to protect the global food supply from diseases, insect pests, and weeds. MustGrow and its leading global partners — Janssen (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 100 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection. Pending regulatory approval, MustGrow’s patented liquid products could be applied through injection, standard drip or spray equipment, improving functionality and performance features. Now a platform technology, MustGrow and its global partners are pursuing applications in several different industries from preplant soil treatment and weed control, to postharvest disease control and food preservation. MustGrow has approximately 49.2 million basic common shares issued and outstanding and 55.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.

MustGrow
Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: (i) potential product approvals; (ii) anticipated actions by partners to drive field development work including dose rates, application frequency, application methods, and the regulatory work necessary for commercialization; (iii) expected product efficacy of MustGrow’s mustard-based technologies; and (iv) expected outcomes from collaborations with commercial partners.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the preferences and choices of agricultural regulators with respect to product approval timelines; (ii) the ability of MustGrow’s partners to meet obligations under their respective agreements; and (iii) other risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2021 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

© 2022 MustGrow Biologics Corp. All rights reserved.